本帖最后由 老马 于 2012-1-13 21:20 编辑
; s5 V0 g; g$ i8 g0 e8 g: i- i6 z2 L" A Z( @
爱必妥和阿瓦斯丁的比较
/ \7 Y# b& w! b* p# t
7 g( L( F: g: d6 O6 v7 Qhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/8 T$ B3 U4 O; u9 t( _
, {, g: h% {: s) A% p# z
/ X3 H0 _. {: U5 ^# v1 A0 u2 Z* T
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/5 k9 o6 G6 l# A$ }3 X: z# n( n7 W
==================================================5 Q/ j' q9 G6 s$ R& K9 O
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
( ^* {8 q7 _: | G3 O4 ^* J2 pPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
& ^6 U$ S7 a% Y1 U" C% |Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
; t) u/ h: \* N+ h( i3 ?: H
|
显身卡
